Nu Skin 10-Q: Q3 Revenue Falls 14.6% to $311.0M; Nine-Month Loss Reaches $248.7M
NUS is trading near its 52-week low of $4.445 (7.8% below the low).
Summary
Nu Skin's Q3 10-Q confirms a 14.6% revenue decline to $311.0 million, a $(0.7) million GAAP loss and a $(248.7) million nine-month loss, with cash down to $164.9 million and operations using $1.4 million of cash year-to-date.
Key Events · Earnings and Guidance · NUS
-
Q3 Revenue Down 14.6% to $311.0M
Revenue fell to $311.0 million from $364.2 million, with a 1.1% FX drag; customers dropped 18%, paid affiliates 10% and sales leaders 13% year over year.
-
GAAP Loss Despite Adjusted Profit
Q3 GAAP net loss was $(0.7) million, or $(0.02) per diluted share, versus $17.1 million ($0.34) a year ago; the nine-month loss reached $(248.7) million, or $(5.13) per share.
-
Impairment and Tax Charge Drive Loss
The nine-month loss reflects the Q2 non-cash $78.9 million goodwill impairment and a $167.5 million valuation allowance against U.S. deferred tax assets.
-
Cash Burn and Shrinking Liquidity
Cash and equivalents fell to $164.9 million from $238.6 million at December 31, 2025; operating activities used $1.4 million in the first nine months versus $63.7 million generated a year earlier.
Analysis · NUS · Trade & Services
The 10-Q fills in the numbers behind Thursday's Q3 release, and they are worse than the headline adjusted EPS suggested: a GAAP net loss of $(0.7) million for the quarter and $(248.7) million for the first nine months, the latter driven by the $78.9 million goodwill impairment and $167.5 million U.S. deferred tax valuation allowance taken earlier this year. Revenue of $311.0 million was down 14.6%, with customers down 18%, paid affiliates down 10% and sales leaders down 13% — the sales force itself is shrinking, which is the engine of a direct-selling model. Cash fell to $164.9 million from $238.6 million at year-end, and operations consumed $1.4 million of cash in the first nine months, against $63.7 million generated a year ago. The filing also discloses that President of Global Sales Justin Keisel steps down effective November 6, 2026, with $608,101 in anticipated severance — a second senior sales departure this quarter after his August medical leave. With the stock near its 52-week low, the balance sheet still supports the $0.06 dividend and $137.3 million buyback authorization, but the cash trend and sales-force attrition are the things that matter from here.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, NUS was trading at $4.10 on NYSE in the Trade & Services sector, with a market capitalization of approximately $220.5M. The 52-week trading range was $4.45 to $11.67. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.